Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
T. Törün, G. Güngör, I. Özmen, G. Ataç, Y. Bölükbasi, B. Biçakçi, K. Tahaoglu (Istanbul, Turkey). Psychiatric issues during the treatment of the patients with multidrug-resistant tuberculosis. Eur Respir J 2005; 26: Suppl. 49, 4461

Member's Comments

No comment yet.

Related content which might interest you: Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Impact of extensive drug resistance on treatment outcomes in non-HIV infected adults with MDR-TB Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009 Childhood tuberculosis in Israel: epidemiological trends and treatment outcomes, 1999–2010 Source: Eur Respir J 2013; 41: 1157-1162 Year: 2013 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 Frequency of risk factors for multi-drug resistant tuberculosis among the patients enrolled at multi-drug resistant clinic in a tertiary care hospital, Pakistan Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 The MTBDRplus 2.0 for rapid diagnosis of multidrug-resistant tuberculosis among patients with high risk of TB resistance Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Multidrug-resistant tuberculosis in UK children: presentation, management and outcome Source: Eur Respir J 2013; 41: 1456-1458 Year: 2013 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012